Haploidentical HSCT: a 15-year experience at San Raffaele.

Abstract

Hematopoietic SCT (HSCT) from HLA haploidentical family donors is a promising therapy for high-risk hematological malignancies. In the past 15 years at San Raffaele Scientific Institute, we investigated several transplant platforms and post transplant cellular-based interventions. We showed that T cell-depleted haploidentical transplantation followed by the infusion of genetically modified donor T cells (TK007 study, Eudract-2005-003587-34) promotes fast and wide immune reconstitution and GvHD control. This approach is currently tested in a phase III multicenter randomized trial (TK008 study, NCT00914628). We targeted patients with advanced leukemia with a sirolimus-based, calcineurin inhibitor-free prophylaxis of GvHD to allow the safe infusion of unmanipulated PBSCs from haploidentical family donors (TrRaMM study, Eudract 2007-5477-54). Results of these approaches are summarized and discussed.

• Authors: C Bonini, J Peccatori, M T L Stanghellini, L Vago, A Bondanza, N Cieri, R Greco, M Bernardi, C Corti, G Oliveira, E Zappone, C Traversari, C Bordignon, F Ciceri
• Journal: Bone marrow transplantation (Bone Marrow Transplant) Vol. 50 Suppl 2 Pg. S67-71 (Jun 2015) ISSN: 1476-5365 [Electronic] England
• PMID: 26039212 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Topics

• Allografts
• Female
• Genetic Engineering
• Graft vs Host Disease (prevention & control)
• Hematopoietic Stem Cell Transplantation (methods)
• Humans
• Leukemia, Myeloid, Acute (therapy)
• Lymphocyte Transfusion
• Male
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (therapy)
• T-Lymphocytes (transplantation)